Prognostic significance of modified Glasgow Prognostic Score in patients undergoing FOLFOXIRI plus bevacizumab therapy for advanced or metastatic colorectal cancer.

IF 2.5 3区医学 Q3 ONCOLOGY

Oncology Pub Date : 2025-05-26 DOI:10.1159/000546260

Koji Numata, Yukari Ono, Kenta Iguchi, Mamoru Uchiyama, Masahiro Asari, Keisuke Kazama, Norio Yukawa, Aya Saito, Manabu Shiozawa

{"title":"Prognostic significance of modified Glasgow Prognostic Score in patients undergoing FOLFOXIRI plus bevacizumab therapy for advanced or metastatic colorectal cancer.","authors":"Koji Numata, Yukari Ono, Kenta Iguchi, Mamoru Uchiyama, Masahiro Asari, Keisuke Kazama, Norio Yukawa, Aya Saito, Manabu Shiozawa","doi":"10.1159/000546260","DOIUrl":null,"url":null,"abstract":"Introduction: The prognostic value of the modified Glasgow Prognostic Score (mGPS), a systemic inflammatory response marker, has been reported in various cancers. However, its role in patients with metastatic colorectal cancer (mCRC) undergoing first-line FOLFOXIRI + bevacizumab (BV) therapy remains unclear. In this study, we aimed to evaluate the prognostic significance of pretreatment mGPS and other inflammatory markers in this patient population.Methods: This study retrospectively reviewed 133 patients with mCRC treated with first-line FOLFOXIRI + BV. We assessed the prognostic value of pretreatment mGPS and other inflammatory markers (NLR, PLR, LMR) in relation to progression-free survival (PFS) and overall survival (OS).Results: Higher mGPS (score 2) was significantly associated with poor PFS and OS. Multivariate analysis identified mGPS 2 as an independent predictor of worse PFS (hazard ratio 2.76, p = 0.004) and OS (hazard ratio 3.43, p < 0.001). No significant associations were found between other inflammatory markers and survival outcomes.Conclusions: Pretreatment mGPS is a simple and useful prognostic factor for mCRC patients receiving FOLFOXIRI + BV therapy and may serve as a convenient indicator for accurate prognosis prediction and treatment decision-making.","PeriodicalId":19497,"journal":{"name":"Oncology","volume":" ","pages":"1-22"},"PeriodicalIF":2.5000,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000546260","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: The prognostic value of the modified Glasgow Prognostic Score (mGPS), a systemic inflammatory response marker, has been reported in various cancers. However, its role in patients with metastatic colorectal cancer (mCRC) undergoing first-line FOLFOXIRI + bevacizumab (BV) therapy remains unclear. In this study, we aimed to evaluate the prognostic significance of pretreatment mGPS and other inflammatory markers in this patient population.

Methods: This study retrospectively reviewed 133 patients with mCRC treated with first-line FOLFOXIRI + BV. We assessed the prognostic value of pretreatment mGPS and other inflammatory markers (NLR, PLR, LMR) in relation to progression-free survival (PFS) and overall survival (OS).

Results: Higher mGPS (score 2) was significantly associated with poor PFS and OS. Multivariate analysis identified mGPS 2 as an independent predictor of worse PFS (hazard ratio 2.76, p = 0.004) and OS (hazard ratio 3.43, p < 0.001). No significant associations were found between other inflammatory markers and survival outcomes.

Conclusions: Pretreatment mGPS is a simple and useful prognostic factor for mCRC patients receiving FOLFOXIRI + BV therapy and may serve as a convenient indicator for accurate prognosis prediction and treatment decision-making.

查看原文本刊更多论文

改良格拉斯哥预后评分在晚期或转移性结直肠癌患者接受FOLFOXIRI联合贝伐单抗治疗中的预后意义

改良的格拉斯哥预后评分（mGPS）是一种全身性炎症反应标志物，已被报道在各种癌症中具有预后价值。然而，它在接受一线FOLFOXIRI +贝伐单抗（BV）治疗的转移性结直肠癌（mCRC）患者中的作用尚不清楚。在这项研究中，我们旨在评估预处理mGPS和其他炎症标志物在该患者群体中的预后意义。方法：本研究回顾性分析了133例一线FOLFOXIRI + BV治疗的mCRC患者。我们评估了预处理mGPS和其他炎症标志物（NLR、PLR、LMR）与无进展生存期（PFS）和总生存期（OS）的预后价值。结果：mGPS（评分2）越高，PFS和OS越差。多因素分析发现mGPS 2是不良PFS（风险比2.76,p = 0.004）和OS（风险比3.43,p < 0.001）的独立预测因子。其他炎症标志物与生存结果之间未发现显著关联。结论：对于接受FOLFOXIRI + BV治疗的mCRC患者，预处理mGPS是一种简单有效的预后因子，可作为准确预测预后和治疗决策的便捷指标。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Oncology 医学-肿瘤学

CiteScore

6.00

自引率

2.90%

发文量

审稿时长

6-12 weeks

期刊介绍： Although laboratory and clinical cancer research need to be closely linked, observations at the basic level often remain removed from medical applications. This journal works to accelerate the translation of experimental results into the clinic, and back again into the laboratory for further investigation. The fundamental purpose of this effort is to advance clinically-relevant knowledge of cancer, and improve the outcome of prevention, diagnosis and treatment of malignant disease. The journal publishes significant clinical studies from cancer programs around the world, along with important translational laboratory findings, mini-reviews (invited and submitted) and in-depth discussions of evolving and controversial topics in the oncology arena. A unique feature of the journal is a new section which focuses on rapid peer-review and subsequent publication of short reports of phase 1 and phase 2 clinical cancer trials, with a goal of insuring that high-quality clinical cancer research quickly enters the public domain, regardless of the trial’s ultimate conclusions regarding efficacy or toxicity.